NASDAQ:IRWD - Ironwood Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.53 +0.05 (+0.40 %) (As of 12/9/2019 09:59 AM ET) Add Compare Today's Range$12.45Now: $12.53▼$12.6850-Day Range$8.70MA: $10.86▼$12.4752-Week Range$7.91Now: $12.53▼$15.21Volume109,562 shsAverage Volume1.54 million shsMarket Capitalization$1.96 billionP/E RatioN/ADividend YieldN/ABeta1.87 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IRWD Previous Symbol CUSIP46333X10 CIK1446847 Webhttp://www.ironwoodpharma.com/ Phone617-621-7722Debt Debt-to-Equity RatioN/A Current Ratio4.88 Quick Ratio4.84Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio25.57 P/E GrowthN/A Sales & Book Value Annual Sales$346.64 million Price / Sales5.67 Cash FlowN/A Price / Cash FlowN/A Book Value($1.27) per share Price / Book-9.87Profitability EPS (Most Recent Fiscal Year)($0.95) Net Income$-282,370,000.00 Net Margins-9.67% Return on Equity-15.83% Return on Assets9.48%Miscellaneous Employees515 Outstanding Shares156,820,000Market Cap$1.96 billion Next Earnings Date2/12/2020 (Estimated) OptionableOptionable Receive IRWD News and Ratings via Email Sign-up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:IRWD Rates by TradingView Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions What is Ironwood Pharmaceuticals' stock symbol? Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD." How were Ironwood Pharmaceuticals' earnings last quarter? Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced its earnings results on Thursday, October, 31st. The biotechnology company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.10 by $0.30. The biotechnology company had revenue of $131.17 million for the quarter, compared to analyst estimates of $97.10 million. Ironwood Pharmaceuticals had a negative return on equity of 15.83% and a negative net margin of 9.67%. The firm's revenue for the quarter was up 99.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.27) EPS. View Ironwood Pharmaceuticals' Earnings History. When is Ironwood Pharmaceuticals' next earnings date? Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Ironwood Pharmaceuticals. What price target have analysts set for IRWD? 10 equities research analysts have issued 1-year price objectives for Ironwood Pharmaceuticals' stock. Their forecasts range from $12.00 to $20.00. On average, they expect Ironwood Pharmaceuticals' stock price to reach $14.67 in the next twelve months. This suggests a possible upside of 17.1% from the stock's current price. View Analyst Price Targets for Ironwood Pharmaceuticals. What is the consensus analysts' recommendation for Ironwood Pharmaceuticals? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ironwood Pharmaceuticals. Has Ironwood Pharmaceuticals been receiving favorable news coverage? Media coverage about IRWD stock has trended somewhat negative on Monday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Ironwood Pharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Ironwood Pharmaceuticals. Who are some of Ironwood Pharmaceuticals' key competitors? Some companies that are related to Ironwood Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Ironwood Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Allergan (AGN) and Continental Resources (CLR). Who are Ironwood Pharmaceuticals' key executives? Ironwood Pharmaceuticals' management team includes the folowing people: Dr. Peter M. Hecht, Co-Founder, CEO & Director (Age 55)Mr. Thomas A. McCourt, Pres (Age 62)Ms. Gina R. Consylman CPA, CFO, Sr. VP & Treasurer (Age 46)Ms. Halley E. Gilbert, Sr. VP, Chief Legal Officer & Sec. (Age 49)Dr. Christopher I. Wright, Chief Devel. Officer & Sr. VP of Global Devel. Who are Ironwood Pharmaceuticals' major shareholders? Ironwood Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (3.72%), Peregrine Capital Management LLC (0.81%), Millennium Management LLC (0.66%), Colony Group LLC (0.33%), Squarepoint Ops LLC (0.25%) and Chicago Equity Partners LLC (0.25%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Kelly Macdonald, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals. Which major investors are selling Ironwood Pharmaceuticals stock? IRWD stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, State Street Corp, SG Americas Securities LLC, First Trust Advisors LP, Broderick Brian C and Chicago Equity Partners LLC. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Kelly Macdonald, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Insider Buying and Selling for Ironwood Pharmaceuticals. Which major investors are buying Ironwood Pharmaceuticals stock? IRWD stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Colony Group LLC, Squarepoint Ops LLC, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, Peregrine Capital Management LLC, First Quadrant L P CA and Redwood Investment Management LLC. View Insider Buying and Selling for Ironwood Pharmaceuticals. How do I buy shares of Ironwood Pharmaceuticals? Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Ironwood Pharmaceuticals' stock price today? One share of IRWD stock can currently be purchased for approximately $12.53. How big of a company is Ironwood Pharmaceuticals? Ironwood Pharmaceuticals has a market capitalization of $1.96 billion and generates $346.64 million in revenue each year. The biotechnology company earns $-282,370,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis. Ironwood Pharmaceuticals employs 515 workers across the globe.View Additional Information About Ironwood Pharmaceuticals. What is Ironwood Pharmaceuticals' official website? The official website for Ironwood Pharmaceuticals is http://www.ironwoodpharma.com/. How can I contact Ironwood Pharmaceuticals? Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected] MarketBeat Community Rating for Ironwood Pharmaceuticals (NASDAQ IRWD)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 450 (Vote Outperform)Underperform Votes: 544 (Vote Underperform)Total Votes: 994MarketBeat's community ratings are surveys of what our community members think about Ironwood Pharmaceuticals and other stocks. Vote "Outperform" if you believe IRWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRWD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/9/2019 by MarketBeat.com StaffFeatured Article: Why are gap-down stocks important?